Myovant Sciences Ltd (MYOV) |
|
15.82 0.36 (2.33%)
|
10-24 22:21 |
|
Open: |
15.35 |
Pre. Close: |
15.46 |
|
High:
|
15.97 |
Low:
|
15.26 |
|
Volume:
|
355,822 |
Market Cap:
|
1,426M |
|
|
|
|
Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix, which is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. The company is also advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The firm is developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
15.997 - 16.074 |
16.074 - 16.143 |
|
Low:
|
15.074 - 15.162 |
15.162 - 15.242 |
|
Close:
|
15.673 - 15.82 |
15.82 - 15.953 |
|
Technical analysis |
as of: 2020-10-23 4:46:56 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 22.62 One year: 26.91 |
| Support: |
Support1: 13.42 Support2: 11.17 |
| Resistance: |
Resistance1: 19.37 Resistance2: 23.04 |
| Pivot: |
15.50  |
| Moving Average: |
MA(5): 15.49  MA(20): 15.56
MA(100): 17.92 MA(250): 14.20 |
| MACD: |
MACD(12,26): -0.80 Signal(9): -0.92 |
| Stochastic oscillator: |
%K(14,3): 57.41 %D(3): 55.16 |
| RSI: |
RSI(14): 44.48 |
| 52-week: |
High: 23.04 Low: 4.14 Change(%): 276.7 |
| Average Vol(K): |
3-Month: 118919 10-Days: 84010 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.MYOV has closed below upper band by 36.6%. Bollinger Bands are 55.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to MYOV's normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Wed, 21 Oct 2020
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids - GlobeNewswire
Thu, 15 Oct 2020
Buy, Sell Or Hold Myovant Sciences Ltd. (NYSE:MYOV) At $15.93? - Marketing Sentinel
Wed, 14 Oct 2020
Myovant Sciences Appoints Ryan Crowe as Vice President, Investor Relations - GlobeNewswire
Wed, 14 Oct 2020
Investors Watch-list: Myovant Sciences Ltd. (MYOV) | Armenian American Reporter - Armenian Reporter
Thu, 08 Oct 2020
Myovant Sciences Ltd. (NYSE:MYOV): Are Analysts Optimistic? - Simply Wall St
Tue, 06 Oct 2020
Hot Aspects to Watch Out: Myovant Sciences Ltd. (MYOV) - Armenian Reporter
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Underperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Underperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
90 |
| Shares Float (M) |
36 |
|
% Held by Insiders
|
59.91 |
|
% Held by Institutions
|
37.60 |
|
Shares Short (K)
|
1,840 |
|
Shares Short P. Month (K)
|
1,760 |
Stock Financials |
|
EPS
|
-2.850 |
|
EPS Est This Year
|
-1.440 |
|
EPS Est Next Year
|
-1.200 |
|
Book Value (p.s.)
|
-1.490 |
|
Profit Margin
|
|
|
Operating Margin
|
-693.90 |
|
Return on Assets (ttm)
|
-76.6 |
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
0.370 |
|
EBITDA (p.s.)
|
-2.544 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-216 |
|
Levered Free Cash Flow (M)
|
-115 |
Stock Valuations |
|
PE Ratio
|
-5.55 |
|
PEG Ratio
|
|
|
Price to Book value
|
-10.62 |
|
Price to Sales
|
42.79 |
|
Price to Cash Flow
|
-6.59 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
